Published ahead of print on October 26, 2006, doi:10.1164/rccm.200602-270OC
© 2007 American Thoracic Society doi: 10.1164/rccm.200602-270OC
Metabolic Risk Factors for Vascular Disease in Obstructive Sleep ApneaA Matched Controlled StudyRoyal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth; and Department of Pulmonary Physiology, Sir Charles Gairdner Hospital, Perth, Australia Correspondence and requests for reprints should be addressed to Nigel McArdle, M.D., Royal Perth Hospital, Respiratory Department Wellington St., 6000, Perth, Western Australia. E-mail: nmcardle{at}cyllene.uwa.edu.au Rationale: Obstructive sleep apnea (OSA) is reported to have a metabolic profile predisposing to cardiovascular disease. However, previous case-control studies have not adequately controlled for confounders. Objectives: To determine whether OSA is associated with increased insulin resistance and related metabolic risk factors. Methods: We performed a matched case-control study (n = 42) examining putative metabolic risks among men with OSA attending a sleep clinic (apneahypopnea index [AHI] > 15] compared with no OSA (AHI < 5). Participants were matched for age ± 5 yr, body mass index ± 10%, and current smoking status. They were free of diabetes, clinically demonstrable cardiovascular disease, marked hypertension, and dyslipidemia.
Measurements and Main Results: Mean ± SD AHI was higher in patients with OSA (40 ± 27) than in control subjects (3 ± 1.3, p = 0.02), and median (interquartile range) nocturnal oxygen saturation was lower (OSA, 83 [7688]; control, 91 [9093]%; p < 0.001). Patients with OSA had a higher median (interquartile range) homeostasis model assessment score for insulin resistance (OSA, 1.7 [0.84.1]; control, 1.0 [0.71.8] mU·mmol/L2; p = 0.02), total cholesterol (OSA, 5.6 [4.86.2]; control, 4.8 [4.35.4] mmol/L; p = 0.049), and low-density-lipoprotein cholesterol (OSA, 3.8 [2.94.2]; control, 3.1 [2.63.6] mmol/L; p = 0.04). Patients with OSA had higher 24-h and nocturnal (12-h) urinary norepinephrine excretion and plasma leptin levels, and lower insulin-like growth factor (IGF)-1 levels (all, p Conclusions: In a sleep clinic population, men with OSA and no identifiable cardiovascular disease have increased insulin resistance and other metabolic changes that act to increase the risk of vascular disease, compared with age- and body mass indexmatched attendees without OSA.
Key Words: sleep disorders pathophysiology vascular disease insulin resistance
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||